Polymorphism of IL-1α, IL-1β and IL-10 in patients with advanced ovarian cancer: Results of a prospective study with 147 patients

• Published in: Gynecologic oncology Vol. 104; no. 3; pp. 680 - 685
• Main Authors: Ioana Braicu, Elena, Mustea, Alexander, Toliat, Mohammad R, Pirvulescu, Cristina, Könsgen, Dominique, Sun, Pengming, Nürnberg, Peter, Lichtenegger, Werner, Sehouli, Jalid
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 2007
• Subjects: Cytokines; Hematology, Oncology and Palliative Medicine; IL-10; IL-1α; IL-1β; Obstetrics and Gynecology; Ovarian cancer; Polymorphism; Cytokines; IL-1β; IL-1α; IL-10; Ovarian cancer; Polymorphism
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2006.10.014

Abstract Objective. Interleukin 1 (IL-1) and IL-10 are critically involved in tumorigenesis. We investigated polymorphisms of IL-1 and IL-10 genes in patients with ovarian cancer (OC). Methods. In a prospective, case–control study 147 patients with OC and 129 patients without history of any malignancy (CG) were genotyped for IL-1 gene ( IL-1α − 889 T/C and IL-1β − 511 C/T) and IL-10 gene ( IL-10 − 1082 G/A, − 819 C/T and − 592 C/A) using pyrosequencing. Results. IL-10 polymorphisms in − 819 and − 592 positions correlated with the postoperative residual tumor mass ( p = 0.036 and p = 0.035, respectively). The chance of achieving optimal tumor debulking was 1.49 times greater for patients with the C/C genotype at − 819 and − 512 positions than for patients with other genotypes. There were no significant associations between allelic frequencies for IL-1α and IL-1β in OC. IL-10 − 819 CC and − 592 CC genotypes were associated in univariate analysis with a better disease-free and overall survival. Conclusions. IL-10 promoter polymorphism may be related with the ability to achieve optimal tumor debulking. Polymorphism in IL-10 gene seems to influence the overall and disease-free survival rate. Subsequent multi-institutional studies with high number of patients are warranted to confirm these results.